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Glucose-6-phosphate dehydrogenase enzyme deficiency in Iranian newborns: 
A systematic review and meta-analysis 
 
 
Abstract 
Background: The aim of this study was to perform a systematic review 
and meta-analysis on available data about glucose-6-phosphate 
dehydrogenase enzyme deficiency (G6PDD) status in Iranian neonates 
screened for the disease. 
Methods: A literature search was conducted in electronic databases of 
Embase, PubMed, Web of Sciences, Scopus and Google Scholar for 
articles published from inception to 1 December 2018. Moreover, the 
literatures from Iranian databases, including Magiran and Scientific 
Information Database were searched. We included observational studies 
reporting prevalence of G6PDD, related complications and genetic factors 
among Iranian neonates. Data were analyzed using STATA software. 
Results: Of 656 articles were initially found, 16 were finally included. 
Overall pooled prevalence of G6PDD was 5.5% (95% confidence 
interval: 2-8.9). Analysis also indicated that boys were significantly 3 
times more at risk of G6PDD compared with girls. Three articles were 
identified related to the jaundice and 4 papers related to kernicterus. A 
range of 43-67% of newborns with G6PDD presents with jaundice. 
Additionally, 5-9% of G6PDD cases with jaundice present with 
kernicterus. One article reported that out of 412 newborns, 12.9% were 
carriers for one of the three G6PD gene mutations, including 
Mediterranean, Chatham and Cosenza. 
Conclusions: Prevalence of G6PDD in Iran is comparable to most 
countries. Jaundice and kernicterus are major complications of G6PDD. 
Therefore, it is necessary to pay attention to all patients with G6PDD. 
Also, it is recommended that hospitals provide the result of G6PD testing 
as soon as possible and before discharging newborn children. 
Keywords: Glucose-6-phosphate dehydrogenase enzyme deficiency, 
G6PD, Hemolytic anemia, Jaundice, Kernicterus 
 
 
 
 
 
 
Introduction 
Glucose-6-phosphate dehydrogenase enzyme deficiency (G6PDD) is 
an X-linked genetic disease caused by mutations in the G6PD gene, and is 
the most common enzymopathy in the world 
[1]
. It is reported that this 
disease worldwide affects approximately 400 million people and 11 
million infants with G6PDD, born every year 
[2, 3]
. G6PDD has a 
prevalence of 5-25% in areas where malaria is endemic, and <5% in non-
endemic areas 
[4]
. G6PD enzyme exists in all body cells and has an 
important role in protecting against oxidative stress. In the patients with 
G6PDD, due to is oxidation of the red blood cell membrane, the cells are 
destroyed, causing hemolysis 
[5]
.  
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Although G6PDD is usually asymptomatic, it can 
have serious clinical features –that is, 
hyperbilirubinemia and jaundice, both of which result 
from an increased rate of hemolysis 
[6, 7]
. One of the 
important risks of hyperbilirubinemia is kernicterus, 
which can cause irreversible neurologic complications 
and permanent developmental disorders observed more 
frequently in neonates 
[8, 9]
. Because the complications 
of G6PDD are more serious in newborns, it is 
necessary to determine the presence of this genetic 
disease early in this age group. 
Health care systems around the world consider a 
screening program as an important and efficient step in 
the reduction of hospitalization caused by favism (a 
form of hemolytic anemia caused by contact with 
broad beans) and also kernicterus. Most of countries 
have this program in neonates 
[10, 11].
 In Iran, there is a 
newborn screening program for G6PDD and it is 
managed by the Ministry of Health and Medical 
Education 
[12]
. We aimed to perform a systematic 
review and meta-analysis on the available data about 
G6PDD prevalence in Iranian neonates screened for the 
disease. In addition, it was tried to collect the 
information related to the genetic factors associated 
with G6PDD and complications which occur following 
the disease. These data should be useful for clinicians 
and other health professionals planning for better 
management of G6PDD in Iranian newborns. 
 
 
Methods 
Information sources and search strategy: A 
literature search was conducted in the electronic 
databases of Embase, PubMed, Web of Sciences, 
Scopus and Google Scholar for articles published from 
inception to 1 December 2018. After searching the 
related terms in the Medical Subject Headings (MeSH) 
database, finally, the keywords included “glucose-6-
phosphate dehydrogenase deficiency” OR 
“Glucosephosphate Dehydrogenase Deficiency” OR 
“Glucose 6 Phosphate Dehydrogenase Deficiency” OR 
“G6PD deficiency” AND “Iran” OR “Iranian”. The 
search was limited to Title/Abstract. The word “Iran” 
was limited to Affiliation as well. Furthermore, the 
current study searched literatures from Iranian 
databases, including Magiran and Scientific 
Information Database (SID), using the Persian 
equivalent of the above-mentioned keywords. Hand 
searching was also performed on the reference lists of 
the relevant review articles and studies finally included 
in the current study to identify additional sources. 
This systematic review and meta-analysis were 
conducted according to the guideline of Preferred 
reporting items for systematic review and meta-
analysis (PRISMA) 
[13]
. The protocol of the present 
study is available in the PROSPERO registry, too 
(CRD42019119693) 
[14]
. 
Inclusion and exclusion criteria: We included 
observational studies reporting the prevalence of 
G6PDD among Iranian neonates. To have an 
acceptable and real prevalence, we included the studies 
screening for G6PDD in newborns, but we excluded 
from further analyses conducted only on the subjects 
with jaundice/hyperbilirubinemia or any other specific 
disease. We included the later studies for assessment of 
complications of G6PDD and genetic factors 
potentially associated with the disease. The other 
exclusion criteria were the following: 
1. Reviews, case reports, editorials, letters and 
comments, 
2. Duplicate articles, 
3. Studies conducted on subjects other than 
neonates, 
4. Articles without clear methodology or results, and 
Full-texts were not available. 
Study selection and data extraction: Two 
authors (MZ, VZ) assessed the Titles and Abstracts 
independently for eligibility. Besides, the full-text of 
the potential articles was evaluated in the next step. 
When there was a discrepancy, it was resolved by 
consensus with a third author (YZ). Two authors (MZ, 
EZ) extracted data independently. The following data 
were collected: first author's name, study period, 
publication date, study location, number of population 
(total and by gender), prevalence of G6PDD among 
screened neonates, prevalence of complications in 
newborns with G6PDD. Duplicate articles were 
excluded and one with more details or larger sample 
size was selected. 
Quality assessment: The checklist by Hoy et al. 
[15]
 was used for evaluating the risk of bias, which has 
nine questions with two potential responses (Yes/No). 
The range of scores is between 0 and 9. Higher scores 
are representative of higher risk of bias. 
Study outcomes and statistical analysis: 
After collecting the necessary data, they were analyzed 
using STATA software (StataCorp, College Station, 
TX, USA). The pooled estimate rate of G6PDD 
prevalence was presented as percent and 95% 
confidence interval (CI). The complications of G6PDD 
in the present study were jaundice (in neonates with 
G6PDD) and kernicterus (in G6PDD cases presented 
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with jaundice). Additionally, the sub-group analyses 
were performed by gender (male and female) and study 
date (<2007 and ≥2007). Splitting the study date into 
<2007 and ≥2007 was mainly based on the distribution 
of the number of reports in each period category. When 
the study date was not mentioned, the year of study 
publication was used instead. Prevalence of G6PDD 
was compared according to gender by using an odds 
ratio (OR) with a 95% confidence interval (CI). I2 
statistic and χ² test were used for checking the 
statistical heterogeneity. Random effects model was 
used for meta-analysis. Forest plots were provided to 
summarize the results of meta-analyses. 
 
 
Results 
A total of 656 articles were initially found by 
searching the databases, of which 198 papers were 
excluded after evaluating title/abstract. After assessing 
full-texts of 35 articles, 19 studies were excluded. 
Different steps of systematic review were indicated in 
PRISMA chart (Figure 1). Overall, 16 studies were 
included in the systematic review for final analysis and 
their details were summarized in table 1. 
 
 
 
 
Figure 1. Prisma Flowchart
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Table 1. Charactritics of the studies reproting prevalence of G6PDD among Iraninan newborns screened for the disease 
Region Author 
Publication 
date 
Study 
date 
Risk of 
bias score 
Number 
(total) 
Number  
(boys) 
Number 
(girls) 
Prevalenc
e  
(%, total) 
Prevalenc
e  
(%, boys) 
Prevalence  
(%, girls) 
Babol 
Zahedpasha 
(54) 
1999 1995 1/9 2046 1035 1011 8.3 12.5 4.1 
Bushehr Movahhed (55) 2003 1998 1/9 415 218 210 8.4 12.8 1.9 
Fars Daliri (56) 2017 
2011-
2015 
1/9 383463 199536 183927 15.6 16.3 14.9 
Isfahahn Iranpour (57) 2008 2006 1/9 2501 1307 1194 3.2 5.1 1 
Mashhad 
Mohammadzad
eh (58) 
2009 2006 1/9 2570 1307 1263 0.8 1 0.5 
Mazandaran Kosaryan (59) 2011 
2007-
2010 
1/9 115622 59430 56192 5.8 - - 
Rafsanjan Alidalaki (60) 2007 2004 1/9 1018 523 495 5 5.7 4.2 
Rasht Khalili (61) 2007 2001 1/9 1197 605 585 6.4 9.8 3.1 
Rasht Keihanian (62) 2016 - 1/9 1474 757 717 6.6 11.4 1.7 
Sari Kosaryan (63) 2014 
2012-
2013 
1/9 365 174 191 7.5 7.5 0 
Semnan Nazari (64) 2011 
2007-
2010 
1/9 9353 4820 4533 3.2 5.5 0.8 
Shahrekord Norbahksh (65) 2013 2011 1/9 1240 633 607 2.3 2 2.6 
Sistan and 
Baluchestan 
Ansari-
Moghaddam 
(66) 
2017 - 1/9 140 68 72 8.4 11.8 5.6 
Tehran 
Abolghasemi 
(17) 
2004 1999 1/9 2000 1006 994 2.1 3.6 0.6 
Tehran Khalesy (16) 2012 
2008-
2009 
1/9 450 245 205 2 3.3 0.5 
Tehran Kazemi (18) 2013 2009 1/9 1226 585 641 2.2 2.1 2.3 
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Table 2. Rate of jaundice in neonates with glucose 6-phosphate dehydrogenase deficiency and kernicterus in 
those presented with jaundice in Iran 
Complication Author Number of subjects Prevalence of complication (%) 
Jaundice Abolghasemi (17) 42 42.9 
 Kazemi (18) 27 70.3 
 Khalesy (16) 9 66.7 
Kernicterus Aletayeb (19) 112 4.5 
 Boskabadi (20) 59 6.8 
 Boskabadi (22) 45 8.9 
 Yousefi (21) 34 8.8 
Prevalence: 
Analysis of 16 articles showed that the overall 
prevalence of G6PDD in Iran was 5.5% (95% CI: 2-
8.9) (Figure 2). The highest rate was for Fars (15.6%) 
and the lowest one pertained to Mashhad, Razavi 
Khorasan (0.8%). In addition, the overall pooled 
prevalence of G6PDD was 7.3% (95% CI: 2.8-11.8) in 
boys and 3.1% (95% CI: 0-7.6) in girls (Figure 3). 
Subgroup analysis by study date indicated that the 
overall estimated prevalence of G6PDD was 4.8% 
(95% CI: 2.8-6.7) based on studies conducted before 
2007, and 5.9% (95% CI: 1.4-10.5) based on studies 
performed after 2007 (Figure 4). Analysis also 
suggested that boys were significantly 3 times more at 
risk of G6PDD than girls (OR=3.1, 95% CI: 1.8-5.3) 
(Figure 5).  
 
Figure 2. The overall pooled prevalence of G6PDD in Iranian newborns 
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Figure 3. The overall pooled prevalence of G6PDD in Iraninan newborns by gender 
Figure 4. The overall pooled prevalence of G6PDD in Iraninan newborns by study date 
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Figure 5. Pooled Odds Ratio (OR) for G6PDD in boys compared with girls 
 
Complications: 
In the present systematic review, also it was tried to 
find the data on the complications of G6PDD among 
Iranian newborns, including jaundice and kernicterus. 
After searching the databases, 3 articles 
[16-18]
 were 
identified related to the jaundice and 4 papers 
[19-22]
 
related to the kernicterus (Table 2). Based on the 
reports, it was determined that a range of 43-67% of 
newborns with G6PDD presented with jaundice. In 
addition, 5-9% of G6PDD cases with jaundice 
presented with kernicterus, too. 
Genetic factors: 
Limited number of articles was found that reported 
genetic factors in G6PDD Iranian newborns. There was 
only one article assessing the frequency of G6PD 
mutations, which was carried out in the North of Iran. 
Mahdavi et al 
[23]
. Stated that 12.9% of 412 newborns 
(8.6% of boys and 16.8% of girls) were carriers for one 
of the three G6PD gene mutations including 
Mediterranean, Chatham and Cosenza. The 
Mediterranean type was the most frequent mutation 
among the three examined molecular mutations. 
One study by Zahedpasha et al 
[24]
. In Northern Iran 
investigated the association between the three 
mutations of G6PD and jaundice. After comparing the 
distribution of Mediterranean and Chatham mutations 
between icteric and non-icteric neonates (both with 
G6PDD), no any significant differences were 
recognized. On the other hand, the distribution of rare 
mutations (Cosenza negative) was significantly higher 
in non-icteric than in icteric newborns. Some mutations 
of G6PD gene may less likely lead to neonatal icterus, 
for example, neonates with the rare Chatham mutation 
are less in need of exchange transfusion, 
A different survey by Zahedpasha et al 
[25]
. 
evaluated any possible relation between neonatal 
icterus and Gilbert syndrome in newborns with 
G6PDD, but no any significant differences were found 
between icteric and non-icteric subjects in the 
distribution of Gilbert syndrome. 
 
 
Discussion: 
In this systematic review and meta-analysis, it was 
determined that the prevalence of G6PDD among 
Iranian newborns was 5.5%. We included the studies in 
which the newborns underwent screening for G6PDD. 
There are different studies about G6PDD prevalence in 
neonates worldwide. For instance, the screening studies 
on neonates demonstrated G6PDD rates as 11.1% in 
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O  (95% CI)
6.  (0.8 , 55.52)
0.  (0.37, 1.62)
7.  (5.12, 10.32)
3.  (2.34, 4.84)
2.  (0.80, 5.55)
5.  (2.86, 9.89)
1.  (0.78, 2.43)
1.  (1.09, 1.13)
6.  (2.56, 14.57)
7.  (2.61, 22.04)
2.  (0.65, 7.91)
3 . 2 (1.89, 542.75)
3.  (1.98, 5.84)
0.  (0.41, 1.88)
7.  (4.08, 13.90)
1 0.00
Weight
3.71
7.14
.97
7.95
6.52
7.44
7.55
8.25
6.80
6.25
5.73
2.53
7.62
.07
7.46
%
  
1.00184 543
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the United States, 
[26]
 4.5% in India, 
[27]
 6.1% in 
Thailand, 
[28]
 2.4% in China, 
[29]
 7.8% in Brazil, 
[30]
 
4.3% in Egypt, 
[31]
 4.4% in Tunisia 
[32]
 and 2% in Saudi 
Arabia 
[33]
. Variable prevalence between different 
countries and regions can be explained by differences 
in ethnicity and genetic distribution between 
populations. Many G6PD gene mutations are 
responsible for deficiency of the enzyme, including 
Mediterranean, Chatham, Cosenza, and G6PD A and 
so on. In a systematic review, only one article was 
found that reported on  the prevalence of G6PD 
mutations among Iranian newborns 
[23]
. 
In a recent meta-analysis concerning Iran, the 
prevalence of Mediterranean, Chatham, and Cosenza 
molecular mutations was estimated 78.2, 9.1 and 0.5% 
in G6PD-deficient people, respectively 
[34]
. 
Mediterranean G6PD has a high prevalence in other 
tropical and subtropical regions 
[24]
. Its prevalence is 
similarly high in neighboring countries, such as Saudi 
Arabia (80%), Oman (74%), Turkey (77%), India 
(60.4%), United Arab Emirates (55.5%) and Pakistan 
(76%), as well as in Mediterranean coast countries 
[34]
. 
This mutation is mainly associated with favism 
[35, 36].
 
Chatham mutation is responsible for G6PDD class II 
presenting with severe hemolytic anemia; however, it 
has lower prevalence compared with the Mediterranean 
mutation 
[37-39]
. 
Our subgroup analysis showed a 3-fold higher rate 
of G6PDD in boys than in girls and risk of G6PDD, a 
result that was consistent with  previous research 
(40)
. 
Considering that inheritance G6PDD has an X-linked 
pattern, it is expected to see this disease more in male 
infants than in female ones. Homozygous males with 
class I mutations usually develop chronic non-
spherocytic hemolytic anemia, whereas females who 
are heterozygous for G6PD can carry severe mutations 
but may remain symptomless 
[41, 42]
. 
Neonatal screening for G6PDD is implemented in 
many Asian, African, Mediterranean and Middle 
Eastern countries where G6PDD is common. Screening 
is associated with a reduced incidence of severe 
hyperbilirubinemia and kernicterus. In countries where 
G6PDD is historically less common, the increase in 
global population movement has raised the question as 
to whether G6PDD screening should be implemented 
throughout the world 
[31, 41]
. 
There was only one article about the relation 
between G6PD mutations, jaundice and its treatment in 
Iranian neonates; Zahedpasha et al 
[24]
. Reported that 
there were no significant relationships between major 
mutations and icterus. A recent meta-analysis on five 
papers represented that infants with G6PDD are about 
4 times more at risk of hyperbilirubinemia compared 
with G6PD-normal infants 
[42]
. 
The current research also discussed kernicterus - a 
major complication of G6PDD. It is clear that G6PDD 
contributes to kernicterus via at least 2 mechanisms: 
firstly, severe hemolysis results in rising total bilirubin 
levels and subsequent accumulation of bilirubin in the 
brain. Secondly, G6PDD results in a reduced buffering 
capacity against bilirubin-induced reactive oxygen 
species 
[43, 44]
. The second mechanism may explain why 
G6PD-deficient infants develop kernicterus at even at 
lower levels of total bilirubin. The risk of kernicterus in 
G6PD-deficient infants with total bilirubin serum 
levels above 20 mg/dL (342 µmol/L) appears to be 
more severe than that associated with rhesus disease. 
Thus, in the presence of G6PDD, even more aggressive 
treatment of these infants is probably indicated
 [45-48]
. 
The incidence of kernicterus in Iran has risen in recent 
years because of a variety of factors: firstly, newborns 
are often discharged from the hospital within 24 to 48 
hours of birth, but total bilirubin levels often peak 4 to 
5 days after birth. Secondly, the lack of proper 
monitoring at home allows the undiagnosed 
development of kernicterus
 [49-52]
. 
One limitation of this systematic review was the 
restricted number of studies evaluating complications 
of G6PDD. The current study suggests the planning of 
new screening studies, and follow-up of the G6PDD 
cases to record the frequency of jaundice and 
kernicterus. Another limitation was the high 
heterogeneities between the studies, despite analyzing 
only the population-based screening studies. However, 
because the individual articles were epidemiologic 
surveys, we would expect high heterogeneity 
[53]
. 
In conclusion, the prevalence of G6PDD in Iran is 
similar to most countries. Jaundice and kernicterus are 
the major complications of G6PDD. Therefore, it is 
necessary to provide good care for patients with 
G6PDD, and it is recommended for those hospitals to 
provide the result of G6PD testing as soon as possible 
after delivery, ideally before discharging newborn 
children. 
 
 
Acknowledgment 
We are grateful to the Clinical Research 
Development Committee of Amirkola Children's 
Hospital and Student Research Committee of Babol 
University of Medical Sciences for their contribution to 
this study. 
  
384 | P a g e              Caspian Journal of Pediatrics, March 2020; Vol 6(No 1), Pp: 376-86 
 
Funding: None. 
Ethical Approval: This study obtained ethics 
committee of Babol University of Medical Sciences 
(IR.MUBABOL.REC.1398.052). 
Conflict of Interest: None declared. 
 
 
References: 
1. Howes RE, Piel FB, Patil AP, et al. G6PD deficiency 
prevalence and estimates of affected populations in 
malaria endemic countries: a geostatistical model-
based map. PLoS Med 2012; 9(11): e1001339. 
2. Domingo GJ, Satyagraha AW, Anvikar A, et al. 
G6PD testing in support of treatment and elimination 
of malaria: recommendations for evaluation of G6PD 
tests. Malar J 2013; 12: 391. 
3. Bhutani VK, Zipursky A, Blencowe H, et al. 
Neonatal hyperbilirubinemia and Rhesus disease of 
the newborn: incidence and impairment estimates for 
2010 at regional and global levels. Pediatr Res 2013; 
74(Suppl 1): 86-100. 
4. Leong A. Is there a need for neonatal screening of 
glucose-6-phosphate dehydrogenase deficiency in 
Canada? Mcgill J Med 2007; 10(1): 31-4. 
5. Arese P, Gallo V, Pantaleo A, Turrini F. Life and 
death of glucose-6-phosphate dehydrogenase (G6PD) 
deficient erythrocytes–role of redox stress and band 3 
modifications. Transfus Med Hemother 2012; 39(5): 
328-34. 
6. Pamba A, Richardson ND, Carter N, et al. Clinical 
spectrum and severity of hemolytic anemia in glucose 
6-phosphate dehydrogenase-deficient children 
receiving dapsone. Blood 2012; 120(20): 4123-33. 
7. Kaplan M, Hammerman C. Glucose-6-phosphate 
dehydrogenase deficiency and severe neonatal 
hyperbilirubinemia: a complexity of interactions 
between genes and environment. Semin Fetal 
Neonatal Med 2010; 15(3): 148-56. 
8. Wusthoff CJ, Loe IM. Impact of bilirubin-induced 
neurologic dysfunction on neurodevelopmental 
outcomes. Semin Fetal Neonatal Med. 2015; 20(1): 
52-7. 
9. Maisels MJ. Managing the jaundiced newborn: a 
persistent challenge. CMAJ. 2015;187(5):335-43. 
10. Cohan N, Karimi M, Khalili AH, Falahzadeh MH, 
Samadi B, Mahdavi RM. The efficacy of a neonatal 
screening programme in decreasing the 
hospitalization rate of patients with G6PD deficiency 
in southern Iran. J Med Screen 2010; 17(2): 66-7. 
11. Arain YH, Bhutani VK. Prevention of Kernicterus in 
South Asia: role of neonatal G6PD deficiency and its 
identification. Indian J Pediatr 2014; 81(6): 599-607. 
12. Kosaryan M, Nasehi MM, Karami H, et al. Neonatal 
screening for G6PD deficiency in Mazandaran 
Province, Iran 2007-2010. Iran J Blood Cancer 2011; 
2(4): 113-6. 
13. Moher D, Liberati A, Tetzlaff J, Altman DG, Group 
P. Preferred reporting items for systematic reviews 
and meta-analyses: the PRISMA statement. PLoS 
Med. 2009;6(7):e1000097. 
14. Available at: 
http://www.crd.york.ac.uk/PROSPERO/display_recor
d.php?ID=CRD42019119693. Accessed on Feb 2, 
2020. 
15. Hoy D, Brooks P, Woolf A, et al. Assessing risk of 
bias in prevalence studies: modification of an existing 
tool and evidence of interrater agreement. J Clin 
Epidemiol 2012; 65(9): 934-9. 
16. Khalesy N, Khosravi N, Haghighi M. Prevalence of 
Glucose-6-phosphate dehydrogenase deficiency in 
neonates born in Tehran-Iran (2008-09). J Gorgan 
Uni Med Sci 2012; 14(1): 100-5. 
17. Abolghasemi H, Mehrani H, Amid A. An update on 
the prevalence of glucose-6-phosphate 
dehydrogenase deficiency and neonatal jaundice in 
Tehran neonates. Clin Biochem 2004; 37(3): 241-4. 
18. Kazemi A, Norouzi H, Moghaddam MT, Naderloo A. 
Prevalence of Glucose-6-phosphate dehydrogenase 
(G6PD) deficiency of newborns in Rasol Akram and 
Ali Asghar hospitals of Tehran. Iran South Med J 
2013; 16(1): 61-8 [Text in Persian]. 
19. Aletayeb SMH, Dehdashtian M, Aramesh MR, et al. 
Outcome of jaundice in neonates with ABO and Rh 
blood incompatibility and glucose-6-phosphate 
dehydrogenase deficiency. Biomed Res 2017; 28(8): 
3440-4. 
20. Boskabadi H, Omidian M, Mafinejad S. Prevalence 
and clinical manifestation of glucose-6-phosphate 
dehydrogenase deficiency in newborns with 
hyperbilirubinemia in Mashhad, Iran. Maced J Med 
Sci 2010; 3(4): 383-7. 
21. Yousefi J, Mirzadeh M, Malek A. The role of 
hemolysis in inducing jaundice in the newborns with 
G6PD deficiency. Iran J Pediatr 2006;16(4):462-6. 
22. Boskabadi H, Maamouri G, Mafinejad S, 
Rezagholizadeh F. Clinical course and prognosis of 
hemolytic jaundice in neonates in North East of Iran. 
Maced J Med Sci 2011; 4(4): 403-7. 
23. Mahdavi MR, Kowsarian M, Roshan P, et al. Carrier 
frequency of three common G6PD gene mutations in 
  
385 | P a g e              Caspian Journal of Pediatrics, March 2020; Vol 6(No 1), Pp: 376-86 
neonates in province of Mazandaran, North of Iran, 
2012. Razi J Med Sci 2014; 21(124): 64-70 [Text in 
Persian]. 
24. Zahedpasha Y, Kachouri MA, Niaki HA, Farhadi R. 
Comparison of molecular mutations of G6PD 
deficiency gene between icteric and nonicteric 
neonates. Int J Mol Cell Med 2013; 2(1): 14-20. 
25. Zahedpasha Y, Ahmadpour M, Niaki HA, Alaee E. 
Relation between Neonatal Icter and Gilbert 
Syndrome in Gloucose-6-Phosphate Dehydrogenase 
Deficient Subjects. J Clin Diagn Res 2014; 8(3): 63-
5. 
26. Nock M, Johnson E, Krugman R, et al. 
Implementation and analysis of a pilot in-hospital 
newborn screening program for glucose-6-phosphate 
dehydrogenase deficiency in the United States. J 
Perinatol 2011; 31(2): 112-7. 
27. Goyal M, Garg A, Goyal MB, et al. Newborn 
screening for G6PD deficiency: A 2-year data from 
North India. Indian J Public Health 2015; 59(2): 145-
8. 
28. Thielemans L, Gornsawun G, Hanboonkunupakarn 
B, et al. Diagnostic performances of the fluorescent 
spot test for G6PD deficiency in newborns along the 
Thailand-Myanmar border: A cohort study. 
Wellcome open Res 2018; 3: 1. 
29. Zhang J, Cui Y, Wang X, et al. Prevalence of 
Glucose-6-Phosphate Dehydrogenase Deficiency in 
Sichuan, China. Clin Lab 2018; 64(3): 383-6. 
30. Castro S, Weber R, Dadalt V, et al. Prevalence of 
G6PD deficiency in newborns in the south of Brazil. 
J Med Screen 2006; 13(2): 85-6. 
31. Elella SA, Tawfik M, Barseem N, Moustafa W. 
Prevalence of glucose-6-phosphate dehydrogenase 
deficiency in neonates in Egypt. Ann Saudi Med 
2017; 37(5): 362–5. 
32. Guellouz N, Ben IM, Ouederni M, et al. Neonatal 
screening of G6PD deficiency in Tunisia. Arch Inst 
Pasteur Tunis 2010; 87(1-2): 69-76. 
33. Muzaffer MA. Neonatal screening of glucose-6-
phosphate dehydrogenase deficiency in Yanbu, Saudi 
Arabia. J Med Screen 2005; 12(4): 170-1. 
34. Moosazadeh M, Nekoei-Moghadam M, ALIRAM–
ZANY M, Amiresmaili M. Identification of mutation 
of Glucose-6-Phosphate Dehy–drogenase (G6PD) in 
Iran: Meta-analysis study. Iran J Public Health 2013; 
42(9): 1007-15. 
35. Luzzatto L, Arese P. Favism and glucose-6-
phosphate dehydrogenase deficiency. New England J 
Med 2018; 378(1): 60-71. 
36. Laosombat V, Sattayasevana B, Chotsampancharoen 
T, Wongchanchailert M. Glucose-6-phosphate 
dehydrogenase variants associated with favism in 
Thai children. Int J Hematol 2006; 83(2): 139-43. 
37. Vulliamy T, D'urso M, Battistuzzi G, et al. Diverse 
point mutations in the human glucose-6-phosphate 
dehydrogenase gene cause enzyme deficiency and 
mild or severe hemolytic anemia. Proc Natl Acad Sci 
U S A 1988; 85(14): 5171-5. 
38. Rahimi Z, Vaisi-Raygani A, Nagel RL, Muniz A. 
Molecular characterization of glucose-6-phosphate 
dehydrogenase deficiency in the Kurdish population 
of Western Iran. Blood Cells Mol Dis 2006; 37(2): 
91-4. 
39. Cappellini MD, Fiorelli G. Glucose-6-phosphate 
dehydrogenase deficiency. Lancet 2008; 371(9606): 
64-74. 
40. Chien Y-H, Lee N-C, Wu S-T, et al. Changes in 
incidence and sex ratio of glucose-6-phosphate 
dehydrogenase deficiency by population drift in 
Taiwan. Southeast Asian J Trop Med Public Health 
2008; 39(1): 154-61. 
41. Watchko J, Kaplan M, Stark A, et al. Should we 
screen newborns for glucose-6-phosphate 
dehydrogenase deficiency in the United States? J 
Perinatol 2013; 33(7): 499-504. 
42. Liu H, Liu W, Tang X, Wang T. Association between 
G6PD deficiency and hyperbilirubinemia in neonates: 
a meta-analysis. Pediatr Hematol Oncol 2015; 32(2): 
92-8. 
43. de Gurrola GC, Araúz JJ, Durán E, et al. Kernicterus 
by glucose-6-phosphate dehydrogenase deficiency: a 
case report and review of the literature. J Med Case 
Reports 2008; 2: 146. 
44. Kaplan M, Hammerman C. Glucose-6-phosphate 
dehydrogenase deficiency: a hidden risk for 
kernicterus. Semin Perinatol 2004; 28(5): 356-64. 
45. Slusher TM, Vreman HJ, McLaren DW, et al. 
Glucose-6-phosphate dehydrogenase deficiency and 
carboxyhemoglobin concentrations associated with 
bilirubin-related morbidity and death in Nigerian 
infants. J Pediatr 1995; 126(1): 102-8. 
46. Brown WR, Boon WH. Hyperbilirubinemia and 
kernicterus in glucose-6-phosphate dehydrogenase-
deficient infants in Singapore. Pediatrics 1968; 41(6): 
1055-62. 
47. Gibbs WN, Gray R, Lowry M. Glucose‐6‐phosphate 
dehydrogenase deficiency and neonatal jaundice in 
Jamaica. Br J Haematol 1979; 43(2): 263-74. 
48. Hannon PR, Willis SK, Scrimshaw SC. Persistence of 
maternal concerns surrounding neonatal jaundice: an 
  
386 | P a g e              Caspian Journal of Pediatrics, March 2020; Vol 6(No 1), Pp: 376-86 
exploratory study. Arch Pediatrs Adoles Med 2001; 
155(12): 1357-63. 
49. Olusanya BO, Ogunlesi TA, Slusher TM. Why is 
kernicterus still a major cause of death and disability 
in low-income and middle-income countries? Arch 
Dis Child 2014; 99(12): archdischild-2013-305506. 
50. Watchko JF. Identification of neonates at risk for 
hazardous hyperbilirubinemia: emerging clinical 
insights. Pediatr Clin North Am 2009; 56(3): 671-87. 
51. Ives K. Preventing kernicterus: a wake-up call. Arch 
Dis Child Fetal Neonatal Ed 2007; 92(5): F330-F1. 
52. Bhutani V, Johnson L. Kernicterus in the 21st 
century: frequently asked questions. J Perinatol 2009; 
29(Suppl 1): S20-4. 
53. Zamani M, Derakhshan M, Zamani V, 
Shokri‐Shirvani J. The prevalence of Helicobacter 
pylori infection worldwide knowns and unknowns. 
Authors' reply. Aliment Pharmacol Ther 2018; 47(9): 
1331-2. 
54. ZahedPasha Y. The prevalence of G6PD deficiency 
in the newborns of Babol, 1995. J Babol Univ Med 
Sci 1999; 1(4): 19-25 [Text in Persian]. 
55. Movahhed A, Farrokhi S. Incidence Rate of G6PD 
Deficiency in Newborns in Bushehr/Iran. Iran J 
Pediatr 2003; 13(1): 55-8 [Text in Persian]. 
56. Daliri S, Asadollahi K, Rahimi N, Sayehmiri K. 
Incidence of glucose-6-phosphate dehydrogenase 
deficiency in malaria-prone regions of Fars province. 
Tehran Univ Med J 2017; 75(9): 669-74 [Text in 
Persian]. 
57. Iranpour R, Hashemipour M, Talaei S-M, et al. 
Newborn screening for glucose-6-phosphate 
dehydrogenase deficiency in Isfahan, Iran: a 
quantitative assay. J Med Screen 2008; 15(2): 62-4. 
58. Mohammadzadeh A, Jafarzadeh M, Farhat AS, et al. 
Prevalence of glucose-6-phosphate dehydrogenase 
deficiency in neonates of Northeast of Iran. J Clin 
Med Res 2009; 4(8). 
59. Kosaryan M, Mahdavi M, Jalali H, Roshan P. 
Comparison of fluorescent spot test, decolorization 
test and quantitative enzyme assay in detection of 
G6PD enzyme deficiency. J Gorgan Uni Med Sci. 
2015;17(3): 108-13 [Text in Persian]. 
60. Alidalaki S, Negahban BT, Houlakouei M, et al. 
Investigation of glucose-6-phosphate dehydrogenase 
deficiency in Rafsanjan, Autumn 2004. J Rafsanjan 
Univ Med Sci 2008 [Text in Persian]. 
61. Khalili D, Jafroodi M, Sajedi S, et al. Survey of the 
prevalence of glucose-6-phosphate dehydrogenase 
deficiency in Rasht-Iran. J Guilan Uni Med Sci 2007; 
16(63): 51-6 [Text in Persian]. 
62. Keihanian F, Basirjafari S, Darbandi B, Saeidinia A, 
Jafroodi M, Sharafi R, et al. Comparison of 
quantitative and qualitative tests for 
glucose‐6‐phosphate dehydrogenase deficiency in the 
neonatal period. Int J Lab Hematol 2017; 39(3): 251-
60. 
63. Kosaryan M, Mahdavi MR, Jalali H, Roshan P. Why 
does the Iranian national program of screening 
newborns for G6PD enzyme deficiency miss a large 
number of affected infants? Pediatr Hematol Oncol. 
2014;31(1):95-100. 
64. Nazari H, Habibeh Najar H, Emadi A, et al. 
Prevalence of G6PD deficiency in neonates referred 
to Semnan University of Medical Science´s screening 
Lab. Medical Laboratory Journal. 2011;5(2):66-70 
[Text in Persian]. 
65. Norbahksh Smk, Kasiri k-A, Jalil A, Hashemzade m. 
Determining the frequency of glucose-6-phosphate 
dehydrogenase deficiency in newborn infants in 
Shahrekord. J of Shahrekord Uuniversity of Medical 
Sciences. 2013;15(5):30-7 [Text in Persian]. 
66. Ansari-Moghaddam A, Adineh HA, Mohammadi M, 
et al. Prevalence of glucose-6-phosphate 
dehydrogenase (G6PD) defiiency in malaria endemic 
region of Iran (Sistan and Baluchestan Province): 
Epidemiological profie and trends over time. Asian 
Pac J Trop Dis 2017; 7(10): 587-91.  
 
